905579-51-3

Basic information

• Product Name: Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester
• Synonyms: ((1S,2S,4R)-4-(4-(((S)-2,3-dihydro-1H-inden-1-yl)aMino)-7H-pyrrolo[2,3-d]pyriMidin-7-yl)-2-hydroxycyclopentyl)Methyl sulfaMate;[(1S,2S,4R)-4-(4-{[(1S)-2,3-dihydro-1H-inden-1-yl]aMino}-7H-pyrrolo[2,3-d]pyriMidin-7-yl)-2-hydroxycyclopentyl]Methyl sulfaMate;Pevonedistat;MLN4924 (Pevonedistat);Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimi;MLN 4924;Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester
• CAS NO: 905579-51-3
• Molecular Formula: C21H25N5O4S
• Molecular Weight: 443.5193
• Product Categories: Bases & Related Reagents;Carbohydrates & Derivatives;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Nucleotides;Pharmaceuticals
• Mol File: 905579-51-3.mol

Chemical Properties

• Melting Point: 161-163°C
• Boiling Point: 721.0±70.0 °C at 760 mmHg
• Flash Point: 389.9±35.7 °C
• Appearance: White Solid
• Density: 1.62
• Storage Temp.: -20?C Freezer
• Solubility: Soluble in DMSO (up to 10 mg/ml).
• PKA: 9.35±0.70(Predicted)
• Stability: Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months.
• CAS DataBase Reference: Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester(905579-51-3)
• EPA Substance Registry System: Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester(905579-51-3)

Safety Data

• Hazardous Substances Data: 905579-51-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester is used as a potent and selective NEDD8-activating enzyme (NAE) inhibitor for the development of novel cancer treatments. It disrupts cullin-RING ligase-mediated protein turnover, leading to apoptosis in human tumor cells and suppressing the growth of human tumor xenografts in mice.
Used in Immunotherapy:
In the field of immunotherapy, Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester is used to upregulate PD-L1 expression, enhancing the efficacy of immune checkpoint blockade in glioblastoma and potentially other cancer types.
Used in Tumor Microenvironment Modulation:
Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester is employed to modulate the tumor microenvironment, which can be crucial for the effectiveness of various cancer therapies and improving patient outcomes.
Used in Drug Development:
As a potent NAE inhibitor, Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester serves as a key component in the development of new drugs targeting the ubiquitin-proteasome pathway, which mediates the destruction of unwanted proteins in cells. This makes it a valuable asset in the search for innovative cancer therapies.

Enzyme inhibitor

This first-in-class small molecule inhibitor (FW = 443.52 g/mol; CAS 905579-51-3; Solubility = 10 mg/mL DMSO), also named MLN4924 and [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3- d]pyrimidin-7-yl]-2-hydroxycyclopentyl]sulfamate methyl ester, targets Nedd8 activating enzyme, or NAE (IC50 = 4.7 nM), with much weaker action against UAE (IC50 = 1.5 μM), SAE (IC50 = 8.2 μM), and UBA6 (IC50 = 1.8 μM). In most cancer cells, pevonedistat treatment results in the induction of DNA re-replication, resulting in DNA damage and cell death. MLN4924 also exhibits an alternative mechanism of action. Treatment of activated B cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) cells with pevonedistat resulted in rapid accumulation of pIkBa, decrease in nuclear p65 content, reduction of transcriptional activity of NF-kB (or nuclear factor k-light-chain-enhancer of activated B cells), and G1 arrest, ultimately resulting in apoptosis induction, events consistent with potent NF-kB pathway inhibition. Treatment of germinal-center B cell-like (GCB) DLBCL cells resulted in an increase in cellular Cdt-1 and accumulation of cells in S-phase, consistent with cells undergoing DNA rereplication. Pevonedistat also inhibits Vpx/Vpr-induced SAMHD1 degradation by inhibiting the neddylation of E3 ubiquitin-ligase and blocking SIVmac replication in myeloid cells, therebyindicating the potential efficacy of inhibiting neddylation as an antiretroviral strategy

References

1) Soucy, et al. (2009), An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458 732 2) Milhollen, et al. (2010) MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-(kappa)B-dependent lymphoma. Blood, 116 1515 3) Zhou et al. (2019) Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma; Int. J. Cancer, 145 763 4) Zhou et al. (2019) Neddylation: a novel modulator of the tumor microenvironment; Mol. Cancer 18 77

Upstream product

• 1281922-74-4 6-(tert-butyldiphenylsilanyloxymethyl)-2,2-dimethyltetrahydrocyclopenta[1,3]dioxol-4-one 
• 1281922-76-6 6-(tert-butyldiphenylsilanyloxymethyl)-2,2-dimethyltetrahydrocyclopenta[1,3]dioxol-4-ol 
• 1281922-73-3 3-tert-butoxy-4-(tert-butyldiphenylsilanyloxymethyl)-cyclopentane-1,2-diol 
• 1281922-80-2 2-tert-butoxy-3-(tert-butyl-diphenyl-silanyloxymethyl)-5-[4-(indan-1-ylamino)-pyrrolo[2,3-d]pyrimidin-7-yl]-cyclopentanol 
• 1281922-81-3 {7-[3-tert-butoxy-4-(tert-butyl-diphenyl-silanyloxymethyl)-cyclopentyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-indan-1-yl-amine 
• 1281922-83-5 sulfamic acid 2-tert-butoxy-4-[4-(indan-1-ylamino)-pyrrolo[2,3-d]pyrimidin-7-yl]-cyclopentylmethyl ester 
• 303963-92-0 (3aR,6aR)-6-(((tert-butyldiphenylsilyl)oxy)methyl)-2,2-dimethyl-3a,6a-dihydro-4H-cyclopenta[d][1,3]dioxol-4-one 
• 1281922-85-7 C₂₆H₃₆O₅SSi 
• 1281922-72-2 (4-tert-butoxy-2,2-dioxo-tetrahydro-2-yl-6-cyclopenta[1,3,2]-dioxathiol-5-ylmethoxy)-tert-butyl-diphenyl-silane 
• 1281922-90-4 C₄₈H₅₄N₄O₄SSi 
• 1113025-23-2 [(1S,3S,5S)-3-(tritylamino)-6-oxabicyclo[3.1.0]hex-1-yl]methanol 
• 1113025-24-3 (1S,2S,4R)-2-(hydroxymethyl)-4-(tritylamino)cyclopentanol 
• 79200-56-9 (-)-2-azabicyclo[2.2.1]hept-5-en-3-one 
• 1007126-28-4 (1S,2S,4R)-4-amino-2-(hydroxymethyl)cyclopentanol 

Relevant articles and documents

Preparation of Sulfamates and Sulfamides Using a Selective Sulfamoylation Agent

Sulfamates and sulfamides are prevalent in biological molecules, but their universal synthetic methods are limited. We herein report a sulfamoylation agent with high solubility and shelf stability. Various sulfamates and sulfamides can be synthesized directly from alcohols or amines by employing this agent with high selectivity and high yields. This protocol was also successfully used for late-stage sulfamoylation of pharmaceuticals containing a hydroxyl or amino group.

Catalytic Sulfamoylation of Alcohols with Activated Aryl Sulfamates

We report a new catalytic method for alcohol sulfamoylation that deploys electron-deficient aryl sulfamates as activated group transfer reagents. The reaction utilizes the simple organic base N-methylimidazole, proceeds under mild conditions, and provides

Process Development and GMP Production of a Potent NAE Inhibitor Pevonedistat

A practical synthesis of a novel NEDD8-activating enzyme (NAE) inhibitor pevonedistat (MLN4924) is described. Key steps include an enantioselective synthesis of an amino-diol cyclopentane intermediate containing three chiral centers and a novel, regiosele

PREPARATION METHOD OF MLN4924 AS AN E1 ACTIVATING INHIBITOR

The present invention relates to a method for preparation of MLN4924 as an E1 activating inhibitor, and more specifically, to a method for efficient and stereoselective preparation of MLN4924 by means of key steps involving stereoselective reduction of cy

Stereoselective synthesis of MLN4924, an inhibitor of NEDD8-activating enzyme

MLN4924 (1), which is in clinical trials as an anticancer agent, was stereoselectively synthesized from d-ribose via a route involving stereoselective reduction, regioselective cleavage of an isopropylidene moiety, and selective displacement of a cyclic s

HYDROCHLORIDE SALT OF ((1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO]-7H-PYRROLO [2,3-D]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTYL)METHYL SULFAMATE

Disclosed is a compound of formula (I); crystalline forms thereof, and solvates thereof; pharmaceutical compositions comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and a pharmaceutically acceptable carrier or diluent; and the use of a compound of formula (I), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting an El activating enzyme, particularly NAE, including, e.g., cancer.

Inhibitors of E1 activating enzymes

This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.

INHIBITORS OF E1 ACTIVATING ENZYMES

This invention relates to compounds that inhibit El activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.